Pharmaceuticals, Biotechnology and Life Sciences
BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that…
Third-quarter revenue $2,769 million Adjusted EBITDA $593 million GAAP Diluted Earnings per Share $0.29; Adjusted Diluted Earnings per Share $1.60…
Total revenues of $57.6 billion, reflecting 9% growth. Loss per diluted share of $(3.99) and Adjusted Earnings per diluted share…
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass.–(BUSINESS WIRE)–$ARQL #arql—ArQule, Inc. (Nasdaq: ARQL) today announced its financial results…
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies…
Pre-NDA Meeting Supports Registration Strategy for Tazemetostat for Follicular Lymphoma Patients with and without EZH2 Activating Mutations and Planned NDA…
–Nonprofit issues challenge to accelerate treatments for every person with CF–
– Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed…
Hemlibra was approved for hemophilia A without inhibitors in Taiwan on 22 October 2019.
NMOSD is a rare disease where repeated relapses may result in visual impairment and motor disability in the course of…